Cardio-Oncology - "Transversals": A practical and useful new term for multidisciplinarity;Cardio-oncologie

Oncologie

Volumn 5, Issue 3, 2003, Pages 147-154

  Ferrari, E ^a   Gligorov, Joseph ^b  

^a PASTEUR HOSPITAL   (France)

^b HÔPITAL TENON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; FLUOROURACIL; TAXANE DERIVATIVE; TRASTUZUMAB;

CARDIOTOXICITY; CHILDHOOD CANCER; CLINICAL PRACTICE; DRUG EFFICACY; DRUG SAFETY; HEART PROTECTION; HEART TUMOR; HUMAN; INCIDENCE; LYMPHOMA; NONHODGKIN LYMPHOMA; REVIEW;

EID: 0042656404     PISSN: 12923818     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (41)

1. Benefit of a high-dose epirubicin regimen in adjuvant chemotherapy for node-positive breast cancer patients with poor prognostic factors: 5-year follow-up results of French Adjuvant Study Group 05 randomized trial (2001) J Clin Oncol 19: 602-11
2. Bleyer WA (1990) The impact of childhood cancer on the United States and the world. CA Cancer J Clin 40: 355-67
3. Bristow MR, Mason JW, Billingham ME, Daniels JR (1978) Doxorubicin cardiomyopathy: evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88: 168-75
4. Crone SA, Zhao YY, Fan L, et al. (2002) ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 8: 459-65
5. Early Breast Cancer Trialists' Collaborative Group (1998) Polychemotherapy for early breast cancer: an overview of the randomised trials. Lancet 352: 930-42
6. Epirubicin-based chemotherapy in metastatic breast cancer patients: role of dose-intensity and duration of treatment (2000) J Clin Oncol 18: 3115-24
7. Ferrari E, Ferrari P, Talbodec A, Baudouy M (1999) Is Troponin I of prognostic value in the detection of anthracyclin cardiac toxicity. Eur Heart J 20: S 621
8. Ferrari E, Taillan B, Dujardin P (1993) Toxicité cardiaque des anthracyclines. Presse Med 21: 999-1004
9. Ferrari E, Taillan B, Morand P (1992) Toxicité Cardiaque du 5FU, aspects typiques et atypiques. A propos de 8 observations. Ann Cardiol Angeiol 41: 191-5
10. Fossati R, Confalonieri C, Torri V, et al. (1998) Cytotoxic and hormonal treatment for metastatic breast cancer: a systematic review of published randomized trials involving 31,510 women. J Clin Oncol 16: 3439-60
11. Grenier MA, Lipshultz SE (1998) Epidemiology of anthracycline cardiotoxicity in children and adults. Semin Oncol 25 (4 Suppl 10): 72-85
12. Harris L, Batist G, Belt R, et al. (2002) Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma. Cancer 94: 25-36
13. Henderson IC, Berry DA, Demetri GD, et al. (2003) Improved Outcomes From Adding Sequential Paclitaxel but Not From Escalating Doxorubicin Dose in an Adjuvant Chemotherapy Regimen for Patients With Node-Positive Primary Breast Cancer. J Clin Oncol 21: 976-83
14. Herman EH, Zhang J, Lipshultz SE, et al. (1999) Correlation between serum levels of cardiac troponin-T and the severity of the chronic cardiomyopathy induced by doxorubicin. J Clin Oncol 17: 2237-43
15. Hitchcock-Bryan S, Gelber R, Cassady JR, Sallan SE (1986) The impact of induction anthracycline on long-term failure-free survival in childhood acute lymphoblastic leukemia. Med Pediatr Oncol 14: 211-5
16. Jassem J, Pienkowski T, Pluzanska A, et al. (2001) Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial. J Clin Oncol 19: 1707-15
17. Jones SE, Grozea PN, Metz EN, et al. (1979) Superiority of adriamycin-containing combination chemotherapy in the treatment of diffuse lymphoma: a Southwest Oncology Group study. Cancer 43: 417-25
18. Keefe DL (2002) Trastuzumab-associated cardiotoxicity. Cancer 95: 1592-600
19. Legha SS, Benjamin RS, Mackay B, et al. (1982) Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 96: 133-9
20. Lipshultz SE, Colan SD, Gelber RD, et al. (1991) Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood. N Engl J Med 324: 808-15
21. Lipshultz SE, Giantris AL, Lipsitz SR, et al. (2002) Doxorubicin administration by continuous infusion is not cardioprotective: the Dana-Farber 91-01 Acute Lymphoblastic Leukemia protocol. J Clin Oncol 20: 1677-82
22. Lipshultz SE, Lipsitz SR, Mone SM, et al. (1995) Female sex and drug dose as riskfactors for late cardiotoxic effects of doxorubicin therapy for childhood cancer. N Engl J Med 332: 1738-43
23. Nabholtz JM, Pienkowski T, Mackey J, et al. (2003) Phase III trial comparing TAC with FAC in the adjuvant treatment of node positive breast cancer patients: analysis of the BCIRG 001 study. Proc Am Soc Clin Oncol 20: abst 141
24. Noori A, Lindenfeld J, Wolfel E, et al. (2000) Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail 6: 115-9
25. O'Shaughnessy J, Miles D, Vukelja S, et al. (2002) Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 20: 2812-23
26. Okumura H, luchi K, Yoshida T, et al. (2000) Brain natriuretic peptide is a predictor of anthracycline-induced cardiotoxicity. Acta Haematol 104: 158-63
27. Piccart MJ, Cardoso F (2003) New data on chemotherapy in the adjuvant setting. Proc Primary Therapy of Early Breast Cancer. The Breast 12 (Suppl 1): S5
28. Pivot X, Asmar L, Buzdar AU, et al. (2000) A unified definition of clinical anthracycline resistance breast cancer. Br J Cancer 82: 529-34
29. Seidman A, Hudis C, Pierri MK, et al. (2002) Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 20: 1215-21
30. Seymour L, Bramwell V, Moran LA (1999) Use of dexrazoxane as a cardioprotectant in patients receiving doxorubicin or epirubicin chemotherapy for the treatment of cancer. Cancer Prev Control 3: 145-59
31. Siveski-Iliskovic N, Kaul N, Singal PK (1994) Probucol promotes endogenous antioxidants and provides protection against adriamycin-induced cardiomyopathy in rats. Circulation 89: 2829-35
32. Slamon DJ, Leyland-Jones B, Shak S, et al. (2001) Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344: 783-92
33. Smith MA, Ungerleider RS, Horowitz ME, Simon R (1991) Influence of doxorubicin dose intensity on response and outcome for patients with osteogenic sarcoma and Ewing's sarcoma. J Natl Cancer Inst 83: 1460-70
34. Sparano JA (2001) Cardiac toxicity of trastuzumab (Herceptin): implications for the design of adjuvant trials. Semin Oncol 28 (Suppl 3): 20-7
35. Steinherz LJ, Graham T, Hurwitz R, et al. (1992) Guidelines for cardiac monitoring of children during and after anthracycline therapy: report of the Cardiology Committee of the Childrens Cancer Study Group. Pediatrics 89: 942-9
36. Steinherz LJ, Steinherz PG, Tan C (1995) Cardiac failure and dysrhythmias 6-19 years after anthracycline therapy: a series of 15 patients. Med Pediatr Oncol 24: 352-61
37. Stoddard MF, Seeger J, Liddell NE, et al. (1992) Prolongation of isovolumetric relaxation time as assessed by Doppler echocardiography predicts doxorubicin-induced systolic dysfunction in humans. J Am Coll Cardiol 20: 62-9
38. Tham YL, Verani MS, Chang J (2002) Reversible and irreversible cardiac dysfunction associated with trastuzumab in breast cancer. Breast cancer research and treatment 74: 131-4
39. Von Hoff DD, Layard MW, Basa P, et al. (1979) Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med 91: 710-7
40. Wigler N, Inbar M, O'Brien M, et al. (2002) Reduced cardiac toxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin (caelyx/doxil) vs doxorubicin for first-line treatment of metastatic breast cancer. Proc Am Soc Clin Oncol 20: abst 177
41. SOR Savoir. Comprendre le cancer du sein. Guide d'information et de dialogue à l'usage des patientes et de leurs proches. FNCLCC (FNCLCC, 101, rue de Tolbiac, F-75013 Paris)